Table 1.
Baseline characteristics of the study groups: Japanese data
| Tocilizumab | |||
|---|---|---|---|
| Characteristic | Placebo | 4 mg/kg | 8 mg/kg |
| n | 53 | 54 | 55 |
| Age (years) | 53 | 54 | 56 |
| Sex (male/female) | 14/39 | 14/40 | 9/46 |
| RA duration (years) | 8.4 | 7.3 | 8.3 |
| Previous DMARD use | 5 | 4 | 5 |
| Tender joint count | 18 ± 8 | 19 ± 9 | 18 ± 10 |
| Swollen joint count | 14 ± 6 | 16 ± 9 | 14 ± 7 |
| ESR (mm/hour) | 69 ± 31 | 71 ± 29 | 67 ± 31 |
| CRP (mg/dl) | 5.5 ± 4.2 | 4.7 ± 2.9 | 4.5 ± 3.3 |
CRP, C-reactive protein; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; RA, rheumatoid arthritis. Adapted, with permission, from [12].